Skip to content

Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain

A Randomized Controlled Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02460692
Enrollment
131
Registered
2015-06-02
Start date
2016-12-31
Completion date
2020-03-25
Last updated
2023-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cannabis, Low Back Pain, Neuropathic Pain

Brief summary

This study will involve treating low back pain associated with nerve injury with oral delta-9-tetrahydrocannabinol (Δ9-THC) or whole plant cannabis for eight weeks. Research subjects will consume either oral Δ9-THC (dronabinol), vaporized 3.7% Δ9-THC/5.6% CBD, or placebo. An analysis will then be determined to assess the risk--benefit ratio of dronabinol and vaporized 3.7% Δ9-THC/5.6% CBD .

Detailed description

The present study is designed to assess whether treatment with vaporized cannabis or dronabinol (oral Δ9-THC) reduces spontaneous and evoked pain more than placebo, and whether there are any differences between the two active treatments in terms of interference with activities of daily living. This study also aims to examine the effects of vaporized whole plant cannabis and dronabinol on mood, neuropsychological function, and psychomimetic side-effects (high, stoned, etc.) compared to placebo and to each other. In addition, we plan to examine the acute effects (after receiving stable treatment for 4 weeks) of vaporized cannabis and dronabinol compared to placebo and each other on driving skills.

Interventions

DRUGPlacebos

Administration of vaporized cannabis plus either dronabinol or placebo pill

DRUGdronabinol

Administration of vaporized cannabis plus either dronabinol or placebo pill

DRUGVaporized Cannabis 3.7% THC/5.6% CBD

Administration of vaporized cannabis plus either dronabinol or placebo pill

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
University of California, San Diego
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

Age greater than 18. Presence of chronic low back pain (CLBP) defined as the response to two questions 1) How long has back pain been an ongoing problem for you? 2) How often has low back pain been an ongoing problem for you over the past 6 months? A response of greater than 3 months to question 1 and a response of at least half the days in the past 6 months to question 2 will define CLBP according to the NIH Task Force on Research Standards for Chronic Low Back Pain. The numerical pain intensity must be greater than 3/10 each day during the one-week observation period. To avoid confounding by concurrent medications, participants will have had a stable analgesic regimen that they will continue throughout the study To obviate residual neuropsychological effects from cannabis exposure, participants will be abstinent from this herbal medicine for 7 days prior to study entry.

Exclusion criteria

Presence of another painful condition of greater severity than the neuropathic pain condition which is being studied. History of traumatic brain injury. Clinically significant or unstable medical condition. Individuals with significant cardiovascular, hepatic or renal disease, uncontrolled hypertension, and chronic pulmonary disease (eg, asthma, COPD), will be excluded. If warranted clinically, subjects will undergo laboratory evaluation (blood chemistry, electrocardiogram, urinalysis, toxicology screening for confirmation. Females of childbearing potential will undergo pregnancy testing. A positive result on toxicity screening will exclude individuals from participation. A urine drug test that screens for 5 categories of drugs: marijuana (Δ9-THC), cocaine, amphetamines/methamphetamines, opiates, benzodiazepines and phencyclidine (PCP) will be employed. A positive result for opioids and/or THC will not be exclusionary if the patient is receiving a prescription for an opioid and/or THC. Allergy to sesame oil, lactose, or gelatin Vascular disease, especially Raynauld's syndrome, systolic blood pressure \> 170 mm, diastolic blood pressure \> 100 mm Recent injuries to the upper extremity Cognitive impairment, such as Dementia or Alzheimer's Disease Substance Abuse History: The Substance Abuse Module of the Diagnostic Interview Schedule for the Diagnostic and Statistical Manual (DSM)-IV will be administered to exclude individuals with current substance use disorders. Pregnancy as ascertained by a mandatory commercial pregnancy test Past history of suicide attempt. Cannabis can exacerbate pre-existing schizophrenia, and has been linked to an increase in the risk of suicide in such patients. In patients with bipolar disorder, cannabis use has been associated with worsening of manic and psychotic symptoms. Such findings suggest that cannabis is contraindicated in individuals with serious mental health issues, a line of reasoning that will be observed in the present study by excluding patients in the bipolar/schizoaffective/schizophrenic spectrum. Suicidality. Exposure to cannabis does not lead to depression but it may be associated with suicidal thoughts and attempts. Therefore, the Beck Depression Inventory (BDI)-II will be used to measure suicidal ideation.

Design outcomes

Primary

MeasureTime frameDescription
Numerical Pain Intensity8 weeksThe primary outcome is self-reported daily average numerical pain intensity during the past 24 hours. The numerical pain intensity is an 11-point pain intensity numerical rating scale (PI-NRS), where 0 equals no pain and 10 equals worst possible pain. The time frame includes baseline and weeks 1, 3, 5, 7, 8. Baseline is the pain tensity reported at the first day in the daily diary, before the first dose. The follow-up pain intensities (weeks 1, 3, 5, 7, 8) are the daily diary average pain intensities since the previously reported timepoint.

Secondary

MeasureTime frameDescription
Neuropathic Pain Scale8 weeksThe Neuropathic Pain Scale (NPS) is an 11-point numerical scale consisting of 13 questions that ask ratings of various pain descriptors (including pain intensity, sharpness, burning, aching, cold, sensitivity, itching,unpleasantness, deep, and surface pain). The NPS is scored as the sum of these pain descriptors. Range of scores is from 0 to100. A higher score is a worse score.
Hopkins Verbal Learning Test8 weeksThe Hopkins Verbal Learning Test provides information on the ability to learn and immediately recall verbal information across trials, as well at the ability to retain, reproduce, and recognize this information after a delay. A list of 12 words is presented to the subject over three trials. After each trial, the subject is to recall as many items as possible from the list in any desired order. A 20-minute delay follows the administration of the three trials, after which the subject is asked to recall the list. The ability to learn is represented by the number of correct words, with a score range of 0-36. A higher score indicates better performance.
Grooved Pegboard Test - Dominant Hand8 weeksThe Grooved Pegboard Test is a test of fine motor coordination and speed. Subjects are required to place 25 small metal pegs into holes on a 3 x 3 metal board. All pegs are alike and have a ridge on one side, which corresponds to a notch in each hole on the board. First the dominant hand is tested, and subjects are asked to place the pegs in the holes as fast as they can. This is then repeated with the non-dominant hand, and the total time for each hand is recorded. A higher score indicates worse performance.
Wechsler Adult Intelligence Scale-III Digit Symbol Test8 weeksThe Digit Symbol test measures concentration, psychomotor speed, and graphomotor abilities. This pen and paper test involves having subjects substitute a series of symbols with numbers as quickly and accurately as possible during a 120 second period. The results are expressed as the number of correct substitutions with a score range of 0-133. A higher number indicates better performance.
Profile of Mood States8 weeksThis questionnaire contains 65 words/statements that describe feelings people have. The questionnaire requires the patient to indicate for each word or statement how he or she has been feeling in the past week. There are 6 subscales: tension-anxiety (9 items, score range: 0-36), depression (15 items, range 0-60), anger-hostility (12 items, range 0-48), vigor-activity (8 items, range 0-32), fatigue (7 items, range 0-28), confusion-bewilderment (7 items, range 0-28). The total mood disturbance (TMD) is calculated by adding the scores for tension-anxiety, depression, anger-hostility, fatigue and confusion-bewilderment and then subtracting the score for vigor-activity. The TMD is reported and has a score range of -32 to 200. A higher score indicates worse symptoms.
Beck Depression Inventory II8 weeksThe Beck Depression Inventory is composed of items relating to symptoms of depression such as hopelessness and irritability, cognitions such as guilt or feelings of being punished, as well as physical symptoms such as fatigue, weight loss, and lack of interest in sex. Range of scores is from 0 to 63. A higher score is a worse score.
Locally Developed Psychoactive Effect Scale - Good Drug Effect6 hoursVisual Analogue Scale (VAS) ratings will be presented as a 100-mm horizontal line, anchored on the left with 'not at all' and on the right with 'extremely'. Participants will pencil in a vertical line along the horizontal line that represents their current feeling (questions usually phrased, 'During the past week, did you feel \_\_\_after consuming the vaporized cannabis?'). Ratings will be: any drug effect, a good drug effect, a bad drug effect, high, drunk, impaired, stoned, as if you liked the drug effect, sedated, confused, nauseous, like you desired more of the drug, anxious, down, and very hungry. This is a substudy. A good drug effect is presented. Range of scores is from 0 to 100. A higher score is a worse score.
Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)8 weeksA Task Force was convened by the NIH Pain Consortium, with the goal of developing research standards for chronic low back pain. The results included recommendations for a repeated measures dataset in order to establish greater consistency in reporting in order to facilitate comparisons among studies. The repeated measure minimal dataset is based upon scores based upon the Patient-Reported Outcomes Measurement Information System ® (PROMIS). These items yield a classification of impacts on the lives of patients that range from 1 (least impact) to 42 (greatest impact).
Cold Pressor Test - Pain Sensitivity8 weeksEach Cold Pressure Test will begin with an immersion of the left hand into a warm water bath for 3 min. During this time, blood pressure and heart rate will be measured. After removal of the hand from the warm water, skin temperature of the thumbpad will be recorded and participants will listen to a standardized script describing the procedures. Participants will then immerse the left hand into the cold water bath, and will be instructed to report the first painful sensation after immersion. They will then be asked to tolerate the stimulus as long as possible, but will be permitted to withdraw their hand from the cold water at any point. Maximum immersion time will be 2 min. Latency to first feel pain (pain sensitivity) and latency to withdraw the hand from the water (pain tolerance) will be recorded. Blood pressure and heart rate will be measured before and after each immersion using the arm that was not immersed in the water bath.
Cannabis Withdrawal Scale - Withdrawal IntensityWeek 8 and Week 10The Cannabis Withdrawal Scale is an assessment tool used to quantify the presence and intensity of various withdrawal symptoms (e.g., strange dreams, mood swings, depression, lack of appetite, and an inability to get to sleep). Range of scores for withdrawal intensity is from 0 to 190. A higher score is a worse score.
Driving Simulation (Lane Tracking)270 minutesLane Tracking: This task requires subjects to drive down a straight 2-lane road, maintain a constant speed of 55 mph, maintain appropriate lane position, and respond to divided attention tasks in the upper corners of the screen. The primary outcome is standard deviation of lateral deviation (swerving) with a score range of 0.51 - 3.24. A higher score indicates worse performance. The driving simulation assessments are conducted in a substudy, which only includes completers with a valid driver's license and who agreed to participate in the substudy.
Driving Simulation (Car Following)270 minutesCar Following: This simulation examines the participant's ability to closely match the speed of an automobile in front of them. Participants are to follow a lead vehicle at a safe and constant distance. The primary outcome is coherence between the participant and lead cars (a general correlation \[0-1\] of the participant's ability to accurately track the speed variations of the lead car. A higher score indicates worse performance. The driving simulation assessments are conducted in a substudy, which only includes completers with a valid driver's license and who agreed to participate in the substudy.
Locally Developed Psychoactive Effect Scale - High6 hoursA total of 15 separate VAS ratings will be presented as a 100-mm horizontal line, anchored on the left with 'not at all' and on the right with 'extremely'. Participants will pencil in a vertical line along the horizontal line that represents their current feeling (questions usually phrased, 'During the past week, did you feel \_\_\_after consuming the vaporized cannabis?'). Ratings will be: any drug effect, a good drug effect, a bad drug effect, high, drunk, impaired, stoned, as if you liked the drug effect, sedated, confused, nauseous, like you desired more of the drug, anxious, down, and very hungry. This is a substudy. Drug high will be presented. Range of scores is from 0 to 100. A higher score is a worse score.
Cannabis Withdrawal Scale - Negative Impact of WithdrawalWeek 8, Week 10The Cannabis Withdrawal Scale is an assessment tool used to quantify the presence and intensity of various withdrawal symptoms (e.g., strange dreams, mood swings, depression, lack of appetite, and an inability to get to sleep). The outcome is measured during the tapering period (weeks 8 and 10), at which patients slowly withdrew from medication over two weeks. Range of scores for the negative impact of withdrawal is from 0 to 190. A higher score is a worse score.
Cold Pressor Test - Pain Tolerance8 weeksEach Cold Pressure Test will begin with an immersion of the left hand into a warm water bath for 3 min. During this time, blood pressure and heart rate will be measured. After removal of the hand from the warm water, skin temperature of the thumbpad will be recorded and participants will listen to a standardized script describing the procedures. Participants will then immerse the left hand into the cold water bath, and will be instructed to report the first painful sensation after immersion. They will then be asked to tolerate the stimulus as long as possible, but will be permitted to withdraw their hand from the cold water at any point. Maximum immersion time will be 2 min. Latency to first feel pain (pain sensitivity) and latency to withdraw the hand from the water (pain tolerance) will be recorded. Blood pressure and heart rate will be measured before and after each immersion using the arm that was not immersed in the water bath.
Marijuana Subscale (M-scale) of the Addiction Research Center Inventory8 weeksThe Marijuana subscale (M-scale) of the Addiction Research Center Inventory consists of 12 true or false questions corresponding to symptoms of cannabis intoxication; the minimum and maximum scores are 0 and 12 respectively. A higher score indicates a worse score. The questions were rephrased to evaluate the experience from the past week rather than an acute response to cannabis.

Countries

United States

Participant flow

Participants by arm

ArmCount
Placebos
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo. Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
44
Dronabinol
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain. dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
43
Vaporized Cannabis 3.7% THC/5.6% CBD
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment. Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
44
Total131

Baseline characteristics

CharacteristicDronabinolVaporized Cannabis 3.7% THC/5.6% CBDPlacebosTotal
Age, Continuous48.6 years
STANDARD_DEVIATION 13
47.4 years
STANDARD_DEVIATION 12.3
38.8 years
STANDARD_DEVIATION 13.7
44.9 years
STANDARD_DEVIATION 13.6
Education13.8 Years
STANDARD_DEVIATION 2.4
14.6 Years
STANDARD_DEVIATION 2.6
14.2 Years
STANDARD_DEVIATION 2.2
14.2 Years
STANDARD_DEVIATION 2.39
Ethnicity (NIH/OMB)
Hispanic or Latino
10 Participants8 Participants11 Participants29 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
33 Participants36 Participants33 Participants102 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants2 Participants1 Participants4 Participants
Race (NIH/OMB)
Asian
1 Participants1 Participants0 Participants2 Participants
Race (NIH/OMB)
Black or African American
10 Participants7 Participants7 Participants24 Participants
Race (NIH/OMB)
More than one race
3 Participants4 Participants4 Participants11 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants1 Participants1 Participants
Race (NIH/OMB)
Unknown or Not Reported
6 Participants1 Participants4 Participants11 Participants
Race (NIH/OMB)
White
22 Participants29 Participants27 Participants78 Participants
Sex/Gender, Customized
Gender
Female
20 Participants20 Participants21 Participants61 Participants
Sex/Gender, Customized
Gender
Male
21 Participants23 Participants23 Participants67 Participants
Sex/Gender, Customized
Gender
Transgender (Female to Male)
1 Participants0 Participants0 Participants1 Participants
Sex/Gender, Customized
Gender
Transgender (Male to Female)
1 Participants1 Participants0 Participants2 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 440 / 430 / 44
other
Total, other adverse events
30 / 4431 / 4330 / 44
serious
Total, serious adverse events
0 / 440 / 430 / 44

Outcome results

Primary

Numerical Pain Intensity

The primary outcome is self-reported daily average numerical pain intensity during the past 24 hours. The numerical pain intensity is an 11-point pain intensity numerical rating scale (PI-NRS), where 0 equals no pain and 10 equals worst possible pain. The time frame includes baseline and weeks 1, 3, 5, 7, 8. Baseline is the pain tensity reported at the first day in the daily diary, before the first dose. The follow-up pain intensities (weeks 1, 3, 5, 7, 8) are the daily diary average pain intensities since the previously reported timepoint.

Time frame: 8 weeks

Population: There are missing values.

ArmMeasureGroupValue (MEAN)Dispersion
PlacebosNumerical Pain IntensityBaseline6.03 score on a scaleStandard Deviation 1.65
PlacebosNumerical Pain IntensityWeek 15.97 score on a scaleStandard Deviation 2.01
PlacebosNumerical Pain IntensityWeek 35.65 score on a scaleStandard Deviation 1.56
PlacebosNumerical Pain IntensityWeek 55.47 score on a scaleStandard Deviation 1.77
PlacebosNumerical Pain IntensityWeek 75.26 score on a scaleStandard Deviation 1.8
PlacebosNumerical Pain IntensityWeek 85.22 score on a scaleStandard Deviation 1.92
DronabinolNumerical Pain IntensityWeek 84.19 score on a scaleStandard Deviation 2.02
DronabinolNumerical Pain IntensityBaseline6.11 score on a scaleStandard Deviation 1.65
DronabinolNumerical Pain IntensityWeek 54.89 score on a scaleStandard Deviation 1.88
DronabinolNumerical Pain IntensityWeek 74.35 score on a scaleStandard Deviation 2.02
DronabinolNumerical Pain IntensityWeek 15.80 score on a scaleStandard Deviation 1.62
DronabinolNumerical Pain IntensityWeek 35.67 score on a scaleStandard Deviation 1.62
Vaporized Cannabis 3.7% THC/5.6% CBDNumerical Pain IntensityWeek 15.64 score on a scaleStandard Deviation 1.98
Vaporized Cannabis 3.7% THC/5.6% CBDNumerical Pain IntensityWeek 35.43 score on a scaleStandard Deviation 2.11
Vaporized Cannabis 3.7% THC/5.6% CBDNumerical Pain IntensityWeek 84.45 score on a scaleStandard Deviation 2.11
Vaporized Cannabis 3.7% THC/5.6% CBDNumerical Pain IntensityWeek 54.82 score on a scaleStandard Deviation 2.29
Vaporized Cannabis 3.7% THC/5.6% CBDNumerical Pain IntensityBaseline6.24 score on a scaleStandard Deviation 1.87
Vaporized Cannabis 3.7% THC/5.6% CBDNumerical Pain IntensityWeek 74.72 score on a scaleStandard Deviation 2.23
Comparison: This is the primary comparison.p-value: 0.78unstructured covariance model
Comparison: This is the secondary comparison.p-value: 0.07Unstructured covariance model
Comparison: This is an exploratory comparisonp-value: 0.044Unstructured covariance model
Secondary

Beck Depression Inventory II

The Beck Depression Inventory is composed of items relating to symptoms of depression such as hopelessness and irritability, cognitions such as guilt or feelings of being punished, as well as physical symptoms such as fatigue, weight loss, and lack of interest in sex. Range of scores is from 0 to 63. A higher score is a worse score.

Time frame: 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
PlacebosBeck Depression Inventory IIWeek 17.68 score on a scaleStandard Deviation 8.7
PlacebosBeck Depression Inventory IIWeek 35.76 score on a scaleStandard Deviation 6.59
PlacebosBeck Depression Inventory IIWeek 85.32 score on a scaleStandard Deviation 7.39
PlacebosBeck Depression Inventory IIBaseline8.05 score on a scaleStandard Deviation 7.99
PlacebosBeck Depression Inventory IIWeek 55.32 score on a scaleStandard Deviation 7.07
PlacebosBeck Depression Inventory IIWeek 75.50 score on a scaleStandard Deviation 7.63
DronabinolBeck Depression Inventory IIWeek 55.52 score on a scaleStandard Deviation 6.28
DronabinolBeck Depression Inventory IIWeek 74.36 score on a scaleStandard Deviation 6.49
DronabinolBeck Depression Inventory IIWeek 85.25 score on a scaleStandard Deviation 8.11
DronabinolBeck Depression Inventory IIWeek 15.61 score on a scaleStandard Deviation 5
DronabinolBeck Depression Inventory IIBaseline7.81 score on a scaleStandard Deviation 8.26
DronabinolBeck Depression Inventory IIWeek 35.26 score on a scaleStandard Deviation 6.81
Vaporized Cannabis 3.7% THC/5.6% CBDBeck Depression Inventory IIWeek 86.06 score on a scaleStandard Deviation 9.62
Vaporized Cannabis 3.7% THC/5.6% CBDBeck Depression Inventory IIBaseline7.84 score on a scaleStandard Deviation 8.14
Vaporized Cannabis 3.7% THC/5.6% CBDBeck Depression Inventory IIWeek 15.32 score on a scaleStandard Deviation 6.05
Vaporized Cannabis 3.7% THC/5.6% CBDBeck Depression Inventory IIWeek 35.59 score on a scaleStandard Deviation 7.24
Vaporized Cannabis 3.7% THC/5.6% CBDBeck Depression Inventory IIWeek 76.09 score on a scaleStandard Deviation 8.63
Vaporized Cannabis 3.7% THC/5.6% CBDBeck Depression Inventory IIWeek 56.25 score on a scaleStandard Deviation 8.52
p-value: 0.84unstructured covariance model
p-value: 0.91unstructured covariance model
p-value: 0.75unstructured covariance model
Secondary

Cannabis Withdrawal Scale - Negative Impact of Withdrawal

The Cannabis Withdrawal Scale is an assessment tool used to quantify the presence and intensity of various withdrawal symptoms (e.g., strange dreams, mood swings, depression, lack of appetite, and an inability to get to sleep). The outcome is measured during the tapering period (weeks 8 and 10), at which patients slowly withdrew from medication over two weeks. Range of scores for the negative impact of withdrawal is from 0 to 190. A higher score is a worse score.

Time frame: Week 8, Week 10

Population: Some subjects dropped out before completing the study.

ArmMeasureGroupValue (MEAN)Dispersion
PlacebosCannabis Withdrawal Scale - Negative Impact of WithdrawalWeek 88.42 score on a scaleStandard Deviation 22.9
PlacebosCannabis Withdrawal Scale - Negative Impact of WithdrawalWeek 108.18 score on a scaleStandard Deviation 24
DronabinolCannabis Withdrawal Scale - Negative Impact of WithdrawalWeek 83.42 score on a scaleStandard Deviation 7.22
DronabinolCannabis Withdrawal Scale - Negative Impact of WithdrawalWeek 102.32 score on a scaleStandard Deviation 8.63
Vaporized Cannabis 3.7% THC/5.6% CBDCannabis Withdrawal Scale - Negative Impact of WithdrawalWeek 810.3 score on a scaleStandard Deviation 24.6
Vaporized Cannabis 3.7% THC/5.6% CBDCannabis Withdrawal Scale - Negative Impact of WithdrawalWeek 104.31 score on a scaleStandard Deviation 10.5
Comparison: Change in negative impact of withdrawal from week 8 to week 10 was compared between the two arms.p-value: 0.084Regression, Linear
Comparison: Change in negative impact of withdrawal from week 8 to week 10 was compared between the two arms.p-value: 0.98Regression, Linear
Comparison: Change in negative impact of withdrawal from week 8 to week 10 was compared between the two arms.p-value: 0.085Regression, Linear
Secondary

Cannabis Withdrawal Scale - Withdrawal Intensity

The Cannabis Withdrawal Scale is an assessment tool used to quantify the presence and intensity of various withdrawal symptoms (e.g., strange dreams, mood swings, depression, lack of appetite, and an inability to get to sleep). Range of scores for withdrawal intensity is from 0 to 190. A higher score is a worse score.

Time frame: Week 8 and Week 10

Population: Some subjects dropped out before completing the study.

ArmMeasureGroupValue (MEAN)Dispersion
PlacebosCannabis Withdrawal Scale - Withdrawal IntensityWeek 813.5 score on a scaleStandard Deviation 23.7
PlacebosCannabis Withdrawal Scale - Withdrawal IntensityWeek 1012.7 score on a scaleStandard Deviation 25.1
DronabinolCannabis Withdrawal Scale - Withdrawal IntensityWeek 86.12 score on a scaleStandard Deviation 8.98
DronabinolCannabis Withdrawal Scale - Withdrawal IntensityWeek 106.32 score on a scaleStandard Deviation 10.2
Vaporized Cannabis 3.7% THC/5.6% CBDCannabis Withdrawal Scale - Withdrawal IntensityWeek 812.4 score on a scaleStandard Deviation 25.2
Vaporized Cannabis 3.7% THC/5.6% CBDCannabis Withdrawal Scale - Withdrawal IntensityWeek 109.97 score on a scaleStandard Deviation 20.1
Comparison: Change in withdrawal intensity from week 8 to week 10 was compared between the two arms.p-value: 0.14Regression, Linear
Comparison: Change in withdrawal intensity from week 8 to week 10 was compared between the two arms.p-value: 0.6Regression, Linear
Comparison: Change in withdrawal intensity from week 8 to week 10 was compared between the two arms.p-value: 0.34Regression, Linear
Secondary

Cold Pressor Test - Pain Sensitivity

Each Cold Pressure Test will begin with an immersion of the left hand into a warm water bath for 3 min. During this time, blood pressure and heart rate will be measured. After removal of the hand from the warm water, skin temperature of the thumbpad will be recorded and participants will listen to a standardized script describing the procedures. Participants will then immerse the left hand into the cold water bath, and will be instructed to report the first painful sensation after immersion. They will then be asked to tolerate the stimulus as long as possible, but will be permitted to withdraw their hand from the cold water at any point. Maximum immersion time will be 2 min. Latency to first feel pain (pain sensitivity) and latency to withdraw the hand from the water (pain tolerance) will be recorded. Blood pressure and heart rate will be measured before and after each immersion using the arm that was not immersed in the water bath.

Time frame: 8 weeks

Population: There were missing values

ArmMeasureGroupValue (MEAN)Dispersion
PlacebosCold Pressor Test - Pain SensitivityPain sensitivity Baseline20.0 secondsStandard Deviation 26.5
PlacebosCold Pressor Test - Pain SensitivityWeek 129.4 secondsStandard Deviation 36.9
PlacebosCold Pressor Test - Pain SensitivityWeek 321.9 secondsStandard Deviation 27.5
PlacebosCold Pressor Test - Pain SensitivityWeek 520.9 secondsStandard Deviation 28.4
PlacebosCold Pressor Test - Pain SensitivityWeek 720.4 secondsStandard Deviation 26.6
PlacebosCold Pressor Test - Pain SensitivityWeek 821.1 secondsStandard Deviation 24.3
DronabinolCold Pressor Test - Pain SensitivityWeek 815.8 secondsStandard Deviation 11
DronabinolCold Pressor Test - Pain SensitivityPain sensitivity Baseline18.3 secondsStandard Deviation 21.8
DronabinolCold Pressor Test - Pain SensitivityWeek 520.4 secondsStandard Deviation 24.8
DronabinolCold Pressor Test - Pain SensitivityWeek 721.5 secondsStandard Deviation 25.7
DronabinolCold Pressor Test - Pain SensitivityWeek 123.0 secondsStandard Deviation 31.6
DronabinolCold Pressor Test - Pain SensitivityWeek 318.8 secondsStandard Deviation 22.6
Vaporized Cannabis 3.7% THC/5.6% CBDCold Pressor Test - Pain SensitivityWeek 120.5 secondsStandard Deviation 29.3
Vaporized Cannabis 3.7% THC/5.6% CBDCold Pressor Test - Pain SensitivityWeek 321.0 secondsStandard Deviation 23.5
Vaporized Cannabis 3.7% THC/5.6% CBDCold Pressor Test - Pain SensitivityWeek 823.9 secondsStandard Deviation 30.6
Vaporized Cannabis 3.7% THC/5.6% CBDCold Pressor Test - Pain SensitivityWeek 524.7 secondsStandard Deviation 28.8
Vaporized Cannabis 3.7% THC/5.6% CBDCold Pressor Test - Pain SensitivityPain sensitivity Baseline26.3 secondsStandard Deviation 30.1
Vaporized Cannabis 3.7% THC/5.6% CBDCold Pressor Test - Pain SensitivityWeek 720.9 secondsStandard Deviation 24.7
p-value: 0.19unstructured covariance model
p-value: 0.7unstructured covariance model
p-value: 0.36unstructured covariance model
Secondary

Cold Pressor Test - Pain Tolerance

Each Cold Pressure Test will begin with an immersion of the left hand into a warm water bath for 3 min. During this time, blood pressure and heart rate will be measured. After removal of the hand from the warm water, skin temperature of the thumbpad will be recorded and participants will listen to a standardized script describing the procedures. Participants will then immerse the left hand into the cold water bath, and will be instructed to report the first painful sensation after immersion. They will then be asked to tolerate the stimulus as long as possible, but will be permitted to withdraw their hand from the cold water at any point. Maximum immersion time will be 2 min. Latency to first feel pain (pain sensitivity) and latency to withdraw the hand from the water (pain tolerance) will be recorded. Blood pressure and heart rate will be measured before and after each immersion using the arm that was not immersed in the water bath.

Time frame: 8 weeks

Population: There were some missing values

ArmMeasureGroupValue (MEAN)Dispersion
PlacebosCold Pressor Test - Pain ToleranceBaseline47.2 secondsStandard Deviation 42
PlacebosCold Pressor Test - Pain ToleranceWeek 150.5 secondsStandard Deviation 40.4
PlacebosCold Pressor Test - Pain ToleranceWeek 346.2 secondsStandard Deviation 38
PlacebosCold Pressor Test - Pain ToleranceWeek 541.4 secondsStandard Deviation 39.5
PlacebosCold Pressor Test - Pain ToleranceWeek 761.7 secondsStandard Deviation 53.8
PlacebosCold Pressor Test - Pain ToleranceWeek 837.9 secondsStandard Deviation 35
DronabinolCold Pressor Test - Pain ToleranceWeek 837.5 secondsStandard Deviation 32.4
DronabinolCold Pressor Test - Pain ToleranceBaseline40.6 secondsStandard Deviation 34.1
DronabinolCold Pressor Test - Pain ToleranceWeek 543.6 secondsStandard Deviation 41.5
DronabinolCold Pressor Test - Pain ToleranceWeek 744.2 secondsStandard Deviation 40.4
DronabinolCold Pressor Test - Pain ToleranceWeek 144.8 secondsStandard Deviation 46.9
DronabinolCold Pressor Test - Pain ToleranceWeek 340.0 secondsStandard Deviation 34.3
Vaporized Cannabis 3.7% THC/5.6% CBDCold Pressor Test - Pain ToleranceWeek 160.9 secondsStandard Deviation 48.8
Vaporized Cannabis 3.7% THC/5.6% CBDCold Pressor Test - Pain ToleranceWeek 364.3 secondsStandard Deviation 49.3
Vaporized Cannabis 3.7% THC/5.6% CBDCold Pressor Test - Pain ToleranceWeek 862.3 secondsStandard Deviation 45.8
Vaporized Cannabis 3.7% THC/5.6% CBDCold Pressor Test - Pain ToleranceWeek 560.7 secondsStandard Deviation 45.9
Vaporized Cannabis 3.7% THC/5.6% CBDCold Pressor Test - Pain ToleranceBaseline58.3 secondsStandard Deviation 46
Vaporized Cannabis 3.7% THC/5.6% CBDCold Pressor Test - Pain ToleranceWeek 754.7 secondsStandard Deviation 42.9
p-value: 0.95unstructured covariance model
p-value: 0.78unstructured covariance model
p-value: 0.99unstructured covariance model
Secondary

Driving Simulation (Car Following)

Car Following: This simulation examines the participant's ability to closely match the speed of an automobile in front of them. Participants are to follow a lead vehicle at a safe and constant distance. The primary outcome is coherence between the participant and lead cars (a general correlation \[0-1\] of the participant's ability to accurately track the speed variations of the lead car. A higher score indicates worse performance. The driving simulation assessments are conducted in a substudy, which only includes completers with a valid driver's license and who agreed to participate in the substudy.

Time frame: 270 minutes

ArmMeasureGroupValue (MEAN)Dispersion
PlacebosDriving Simulation (Car Following)After First Dose 230 minutes0.72 score on a scaleStandard Deviation 0.24
PlacebosDriving Simulation (Car Following)After First Dose 100 minutes0.59 score on a scaleStandard Deviation 0.33
PlacebosDriving Simulation (Car Following)Pre Dose0.70 score on a scaleStandard Deviation 0.17
PlacebosDriving Simulation (Car Following)After First Dose 30 minutes0.75 score on a scaleStandard Deviation 0.13
PlacebosDriving Simulation (Car Following)After Second Dose 30 minutes0.74 score on a scaleStandard Deviation 0.19
DronabinolDriving Simulation (Car Following)After First Dose 100 minutes0.68 score on a scaleStandard Deviation 0.2
DronabinolDriving Simulation (Car Following)Pre Dose0.62 score on a scaleStandard Deviation 0.2
DronabinolDriving Simulation (Car Following)After First Dose 30 minutes0.71 score on a scaleStandard Deviation 0.2
DronabinolDriving Simulation (Car Following)After First Dose 230 minutes0.60 score on a scaleStandard Deviation 0.27
DronabinolDriving Simulation (Car Following)After Second Dose 30 minutes0.68 score on a scaleStandard Deviation 0.26
Vaporized Cannabis 3.7% THC/5.6% CBDDriving Simulation (Car Following)After Second Dose 30 minutes0.60 score on a scaleStandard Deviation 0.22
Vaporized Cannabis 3.7% THC/5.6% CBDDriving Simulation (Car Following)After First Dose 230 minutes0.62 score on a scaleStandard Deviation 0.25
Vaporized Cannabis 3.7% THC/5.6% CBDDriving Simulation (Car Following)Pre Dose0.49 score on a scaleStandard Deviation 0.29
Vaporized Cannabis 3.7% THC/5.6% CBDDriving Simulation (Car Following)After First Dose 100 minutes0.56 score on a scaleStandard Deviation 0.22
Vaporized Cannabis 3.7% THC/5.6% CBDDriving Simulation (Car Following)After First Dose 30 minutes0.61 score on a scaleStandard Deviation 0.23
p-value: 0.69unstructured covariance model
p-value: 0.79unstructured covariance model
p-value: 0.97unstructured covariance model
Secondary

Driving Simulation (Lane Tracking)

Lane Tracking: This task requires subjects to drive down a straight 2-lane road, maintain a constant speed of 55 mph, maintain appropriate lane position, and respond to divided attention tasks in the upper corners of the screen. The primary outcome is standard deviation of lateral deviation (swerving) with a score range of 0.51 - 3.24. A higher score indicates worse performance. The driving simulation assessments are conducted in a substudy, which only includes completers with a valid driver's license and who agreed to participate in the substudy.

Time frame: 270 minutes

Population: There are some missing values

ArmMeasureGroupValue (MEAN)Dispersion
PlacebosDriving Simulation (Lane Tracking)After First Dose 230 minutes1.31 score on a scaleStandard Deviation 0.57
PlacebosDriving Simulation (Lane Tracking)After First Dose 100 minutes1.12 score on a scaleStandard Deviation 0.57
PlacebosDriving Simulation (Lane Tracking)Pre Dose0.75 score on a scaleStandard Deviation 0.18
PlacebosDriving Simulation (Lane Tracking)After First Dose 30 minutes1.18 score on a scaleStandard Deviation 0.43
PlacebosDriving Simulation (Lane Tracking)After Second Dose 30 minutes1.13 score on a scaleStandard Deviation 0.47
DronabinolDriving Simulation (Lane Tracking)After First Dose 100 minutes1.78 score on a scaleStandard Deviation 0.87
DronabinolDriving Simulation (Lane Tracking)Pre Dose1.28 score on a scaleStandard Deviation 0.65
DronabinolDriving Simulation (Lane Tracking)After First Dose 30 minutes1.41 score on a scaleStandard Deviation 0.61
DronabinolDriving Simulation (Lane Tracking)After First Dose 230 minutes1.51 score on a scaleStandard Deviation 0.76
DronabinolDriving Simulation (Lane Tracking)After Second Dose 30 minutes1.65 score on a scaleStandard Deviation 0.79
Vaporized Cannabis 3.7% THC/5.6% CBDDriving Simulation (Lane Tracking)After Second Dose 30 minutes1.24 score on a scaleStandard Deviation 0.39
Vaporized Cannabis 3.7% THC/5.6% CBDDriving Simulation (Lane Tracking)After First Dose 230 minutes1.11 score on a scaleStandard Deviation 0.25
Vaporized Cannabis 3.7% THC/5.6% CBDDriving Simulation (Lane Tracking)Pre Dose1.14 score on a scaleStandard Deviation 0.41
Vaporized Cannabis 3.7% THC/5.6% CBDDriving Simulation (Lane Tracking)After First Dose 100 minutes1.21 score on a scaleStandard Deviation 0.35
Vaporized Cannabis 3.7% THC/5.6% CBDDriving Simulation (Lane Tracking)After First Dose 30 minutes1.12 score on a scaleStandard Deviation 0.32
p-value: 0.34unstructured covariance model
p-value: 0.007unstructured covariance model
p-value: 0.055unstructured covariance model
Secondary

Grooved Pegboard Test - Dominant Hand

The Grooved Pegboard Test is a test of fine motor coordination and speed. Subjects are required to place 25 small metal pegs into holes on a 3 x 3 metal board. All pegs are alike and have a ridge on one side, which corresponds to a notch in each hole on the board. First the dominant hand is tested, and subjects are asked to place the pegs in the holes as fast as they can. This is then repeated with the non-dominant hand, and the total time for each hand is recorded. A higher score indicates worse performance.

Time frame: 8 weeks

Population: There were some missing data.

ArmMeasureGroupValue (MEAN)Dispersion
PlacebosGrooved Pegboard Test - Dominant HandBaseline63.7 secondsStandard Deviation 10.6
PlacebosGrooved Pegboard Test - Dominant HandWeek 160.7 secondsStandard Deviation 9.83
PlacebosGrooved Pegboard Test - Dominant HandWeek 361.1 secondsStandard Deviation 14.1
PlacebosGrooved Pegboard Test - Dominant HandWeek 559.9 secondsStandard Deviation 14.8
PlacebosGrooved Pegboard Test - Dominant HandWeek 759.7 secondsStandard Deviation 13.6
PlacebosGrooved Pegboard Test - Dominant HandWeek 860.8 secondsStandard Deviation 18.5
DronabinolGrooved Pegboard Test - Dominant HandWeek 869.2 secondsStandard Deviation 27.6
DronabinolGrooved Pegboard Test - Dominant HandBaseline73.4 secondsStandard Deviation 21.1
DronabinolGrooved Pegboard Test - Dominant HandWeek 569.0 secondsStandard Deviation 23.3
DronabinolGrooved Pegboard Test - Dominant HandWeek 768.7 secondsStandard Deviation 24.9
DronabinolGrooved Pegboard Test - Dominant HandWeek 169.5 secondsStandard Deviation 23.8
DronabinolGrooved Pegboard Test - Dominant HandWeek 363.1 secondsStandard Deviation 10.9
Vaporized Cannabis 3.7% THC/5.6% CBDGrooved Pegboard Test - Dominant HandWeek 164.5 secondsStandard Deviation 13.2
Vaporized Cannabis 3.7% THC/5.6% CBDGrooved Pegboard Test - Dominant HandWeek 364.1 secondsStandard Deviation 11.2
Vaporized Cannabis 3.7% THC/5.6% CBDGrooved Pegboard Test - Dominant HandWeek 861.7 secondsStandard Deviation 12.7
Vaporized Cannabis 3.7% THC/5.6% CBDGrooved Pegboard Test - Dominant HandWeek 561.7 secondsStandard Deviation 12.1
Vaporized Cannabis 3.7% THC/5.6% CBDGrooved Pegboard Test - Dominant HandBaseline69.1 secondsStandard Deviation 14.4
Vaporized Cannabis 3.7% THC/5.6% CBDGrooved Pegboard Test - Dominant HandWeek 762.5 secondsStandard Deviation 13.3
p-value: 0.93unstructured covariance model
p-value: 0.92unstructured covariance model
p-value: 0.85unstructured covariance model
Secondary

Hopkins Verbal Learning Test

The Hopkins Verbal Learning Test provides information on the ability to learn and immediately recall verbal information across trials, as well at the ability to retain, reproduce, and recognize this information after a delay. A list of 12 words is presented to the subject over three trials. After each trial, the subject is to recall as many items as possible from the list in any desired order. A 20-minute delay follows the administration of the three trials, after which the subject is asked to recall the list. The ability to learn is represented by the number of correct words, with a score range of 0-36. A higher score indicates better performance.

Time frame: 8 weeks

Population: Some subjects dropped out before completing the study.

ArmMeasureGroupValue (MEAN)Dispersion
PlacebosHopkins Verbal Learning TestWeek 724.3 Number of correct wordsStandard Deviation 4
PlacebosHopkins Verbal Learning TestWeek 824.0 Number of correct wordsStandard Deviation 4.16
PlacebosHopkins Verbal Learning TestWeek 525.6 Number of correct wordsStandard Deviation 3.84
PlacebosHopkins Verbal Learning TestWeek 322.9 Number of correct wordsStandard Deviation 3.74
PlacebosHopkins Verbal Learning TestBaseline24.1 Number of correct wordsStandard Deviation 5.24
PlacebosHopkins Verbal Learning TestWeek 124.0 Number of correct wordsStandard Deviation 4.78
DronabinolHopkins Verbal Learning TestBaseline23.7 Number of correct wordsStandard Deviation 5.21
DronabinolHopkins Verbal Learning TestWeek 724.7 Number of correct wordsStandard Deviation 4.78
DronabinolHopkins Verbal Learning TestWeek 123.3 Number of correct wordsStandard Deviation 4.44
DronabinolHopkins Verbal Learning TestWeek 524.0 Number of correct wordsStandard Deviation 4.9
DronabinolHopkins Verbal Learning TestWeek 824.5 Number of correct wordsStandard Deviation 4.68
DronabinolHopkins Verbal Learning TestWeek 323.6 Number of correct wordsStandard Deviation 5.04
Vaporized Cannabis 3.7% THC/5.6% CBDHopkins Verbal Learning TestWeek 824.8 Number of correct wordsStandard Deviation 5.53
Vaporized Cannabis 3.7% THC/5.6% CBDHopkins Verbal Learning TestBaseline24.4 Number of correct wordsStandard Deviation 4.9
Vaporized Cannabis 3.7% THC/5.6% CBDHopkins Verbal Learning TestWeek 124.0 Number of correct wordsStandard Deviation 4.44
Vaporized Cannabis 3.7% THC/5.6% CBDHopkins Verbal Learning TestWeek 322.8 Number of correct wordsStandard Deviation 4.08
Vaporized Cannabis 3.7% THC/5.6% CBDHopkins Verbal Learning TestWeek 524.6 Number of correct wordsStandard Deviation 4.55
Vaporized Cannabis 3.7% THC/5.6% CBDHopkins Verbal Learning TestWeek 723.8 Number of correct wordsStandard Deviation 4.99
p-value: 0.95unstructured covariance model
p-value: 0.94unstructured covariance model
p-value: 0.9unstructured covariance model
Secondary

Locally Developed Psychoactive Effect Scale - Good Drug Effect

Visual Analogue Scale (VAS) ratings will be presented as a 100-mm horizontal line, anchored on the left with 'not at all' and on the right with 'extremely'. Participants will pencil in a vertical line along the horizontal line that represents their current feeling (questions usually phrased, 'During the past week, did you feel \_\_\_after consuming the vaporized cannabis?'). Ratings will be: any drug effect, a good drug effect, a bad drug effect, high, drunk, impaired, stoned, as if you liked the drug effect, sedated, confused, nauseous, like you desired more of the drug, anxious, down, and very hungry. This is a substudy. A good drug effect is presented. Range of scores is from 0 to 100. A higher score is a worse score.

Time frame: 6 hours

Population: There are some missing values

ArmMeasureGroupValue (MEAN)Dispersion
PlacebosLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 1 hour14.2 score on a scaleStandard Deviation 24.4
PlacebosLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 2 hours14.0 score on a scaleStandard Deviation 23.8
PlacebosLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 3 hours5.88 score on a scaleStandard Deviation 14.3
PlacebosLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 4 hours7.43 score on a scaleStandard Deviation 15.9
PlacebosLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 5 hours11.6 score on a scaleStandard Deviation 28.5
PlacebosLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 6 hours10.7 score on a scaleStandard Deviation 27
DronabinolLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 6 hours32.4 score on a scaleStandard Deviation 41.4
DronabinolLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 1 hour19.1 score on a scaleStandard Deviation 34.3
DronabinolLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 4 hours36.3 score on a scaleStandard Deviation 42.8
DronabinolLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 5 hours29.7 score on a scaleStandard Deviation 41.9
DronabinolLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 2 hours33.5 score on a scaleStandard Deviation 38.5
DronabinolLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 3 hours33.2 score on a scaleStandard Deviation 44.1
Vaporized Cannabis 3.7% THC/5.6% CBDLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 2 hours45.7 score on a scaleStandard Deviation 31.7
Vaporized Cannabis 3.7% THC/5.6% CBDLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 3 hours27.5 score on a scaleStandard Deviation 29.5
Vaporized Cannabis 3.7% THC/5.6% CBDLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 6 hours40.4 score on a scaleStandard Deviation 35.9
Vaporized Cannabis 3.7% THC/5.6% CBDLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 4 hours37.0 score on a scaleStandard Deviation 37.5
Vaporized Cannabis 3.7% THC/5.6% CBDLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 1 hour58.8 score on a scaleStandard Deviation 32.5
Vaporized Cannabis 3.7% THC/5.6% CBDLocally Developed Psychoactive Effect Scale - Good Drug EffectAfter dose 5 hours44.4 score on a scaleStandard Deviation 34.3
p-value: 0.24Regression, Linear
p-value: 0.08Regression, Linear
p-value: 0.005Regression, Linear
Secondary

Locally Developed Psychoactive Effect Scale - High

A total of 15 separate VAS ratings will be presented as a 100-mm horizontal line, anchored on the left with 'not at all' and on the right with 'extremely'. Participants will pencil in a vertical line along the horizontal line that represents their current feeling (questions usually phrased, 'During the past week, did you feel \_\_\_after consuming the vaporized cannabis?'). Ratings will be: any drug effect, a good drug effect, a bad drug effect, high, drunk, impaired, stoned, as if you liked the drug effect, sedated, confused, nauseous, like you desired more of the drug, anxious, down, and very hungry. This is a substudy. Drug high will be presented. Range of scores is from 0 to 100. A higher score is a worse score.

Time frame: 6 hours

Population: There are some missing values

ArmMeasureGroupValue (MEAN)Dispersion
PlacebosLocally Developed Psychoactive Effect Scale - HighAfter dose 1 hour5.38 score on a scaleStandard Deviation 12.2
PlacebosLocally Developed Psychoactive Effect Scale - HighAfter dose 2 hours5.75 score on a scaleStandard Deviation 14.7
PlacebosLocally Developed Psychoactive Effect Scale - HighAfter dose 3 hours5.56 score on a scaleStandard Deviation 13.2
PlacebosLocally Developed Psychoactive Effect Scale - HighAfter dose 4 hours4.00 score on a scaleStandard Deviation 7
PlacebosLocally Developed Psychoactive Effect Scale - HighAfter dose 5 hours1.75 score on a scaleStandard Deviation 1.83
PlacebosLocally Developed Psychoactive Effect Scale - HighAfter dose 6 hours1.71 score on a scaleStandard Deviation 3.4
DronabinolLocally Developed Psychoactive Effect Scale - HighAfter dose 6 hours24.8 score on a scaleStandard Deviation 38.7
DronabinolLocally Developed Psychoactive Effect Scale - HighAfter dose 1 hour14.9 score on a scaleStandard Deviation 31.5
DronabinolLocally Developed Psychoactive Effect Scale - HighAfter dose 4 hours28.6 score on a scaleStandard Deviation 32.5
DronabinolLocally Developed Psychoactive Effect Scale - HighAfter dose 5 hours21.5 score on a scaleStandard Deviation 36.9
DronabinolLocally Developed Psychoactive Effect Scale - HighAfter dose 2 hours25.8 score on a scaleStandard Deviation 38.1
DronabinolLocally Developed Psychoactive Effect Scale - HighAfter dose 3 hours31.8 score on a scaleStandard Deviation 40.5
Vaporized Cannabis 3.7% THC/5.6% CBDLocally Developed Psychoactive Effect Scale - HighAfter dose 2 hours36.7 score on a scaleStandard Deviation 27.1
Vaporized Cannabis 3.7% THC/5.6% CBDLocally Developed Psychoactive Effect Scale - HighAfter dose 3 hours20.5 score on a scaleStandard Deviation 22.5
Vaporized Cannabis 3.7% THC/5.6% CBDLocally Developed Psychoactive Effect Scale - HighAfter dose 6 hours31.7 score on a scaleStandard Deviation 30.3
Vaporized Cannabis 3.7% THC/5.6% CBDLocally Developed Psychoactive Effect Scale - HighAfter dose 4 hours29.5 score on a scaleStandard Deviation 32.8
Vaporized Cannabis 3.7% THC/5.6% CBDLocally Developed Psychoactive Effect Scale - HighAfter dose 1 hour49.8 score on a scaleStandard Deviation 30.7
Vaporized Cannabis 3.7% THC/5.6% CBDLocally Developed Psychoactive Effect Scale - HighAfter dose 5 hours43.9 score on a scaleStandard Deviation 32.8
p-value: 0.21Regression, Linear
p-value: 0.029Regression, Linear
p-value: 0.001Regression, Linear
Secondary

Marijuana Subscale (M-scale) of the Addiction Research Center Inventory

The Marijuana subscale (M-scale) of the Addiction Research Center Inventory consists of 12 true or false questions corresponding to symptoms of cannabis intoxication; the minimum and maximum scores are 0 and 12 respectively. A higher score indicates a worse score. The questions were rephrased to evaluate the experience from the past week rather than an acute response to cannabis.

Time frame: 8 weeks

Population: There were missing values.

ArmMeasureGroupValue (MEAN)Dispersion
PlacebosMarijuana Subscale (M-scale) of the Addiction Research Center InventoryWeek 71.61 score on a scaleStandard Deviation 2.41
PlacebosMarijuana Subscale (M-scale) of the Addiction Research Center InventoryWeek 51.31 score on a scaleStandard Deviation 2.19
PlacebosMarijuana Subscale (M-scale) of the Addiction Research Center InventoryWeek 11.59 score on a scaleStandard Deviation 2.02
PlacebosMarijuana Subscale (M-scale) of the Addiction Research Center InventoryWeek 31.63 score on a scaleStandard Deviation 2.11
PlacebosMarijuana Subscale (M-scale) of the Addiction Research Center InventoryWeek 81.11 score on a scaleStandard Deviation 1.95
DronabinolMarijuana Subscale (M-scale) of the Addiction Research Center InventoryWeek 52.93 score on a scaleStandard Deviation 2.51
DronabinolMarijuana Subscale (M-scale) of the Addiction Research Center InventoryWeek 11.81 score on a scaleStandard Deviation 1.72
DronabinolMarijuana Subscale (M-scale) of the Addiction Research Center InventoryWeek 32.47 score on a scaleStandard Deviation 2.21
DronabinolMarijuana Subscale (M-scale) of the Addiction Research Center InventoryWeek 72.46 score on a scaleStandard Deviation 2.38
DronabinolMarijuana Subscale (M-scale) of the Addiction Research Center InventoryWeek 82.29 score on a scaleStandard Deviation 2.34
Vaporized Cannabis 3.7% THC/5.6% CBDMarijuana Subscale (M-scale) of the Addiction Research Center InventoryWeek 82.31 score on a scaleStandard Deviation 2.36
Vaporized Cannabis 3.7% THC/5.6% CBDMarijuana Subscale (M-scale) of the Addiction Research Center InventoryWeek 72.80 score on a scaleStandard Deviation 2.47
Vaporized Cannabis 3.7% THC/5.6% CBDMarijuana Subscale (M-scale) of the Addiction Research Center InventoryWeek 12.31 score on a scaleStandard Deviation 2.28
Vaporized Cannabis 3.7% THC/5.6% CBDMarijuana Subscale (M-scale) of the Addiction Research Center InventoryWeek 52.67 score on a scaleStandard Deviation 2.41
Vaporized Cannabis 3.7% THC/5.6% CBDMarijuana Subscale (M-scale) of the Addiction Research Center InventoryWeek 32.33 score on a scaleStandard Deviation 1.91
p-value: 0.6unstructured covariance model
p-value: 0.4unstructured covariance model
p-value: 0.72unstructured covariance model
Secondary

Neuropathic Pain Scale

The Neuropathic Pain Scale (NPS) is an 11-point numerical scale consisting of 13 questions that ask ratings of various pain descriptors (including pain intensity, sharpness, burning, aching, cold, sensitivity, itching,unpleasantness, deep, and surface pain). The NPS is scored as the sum of these pain descriptors. Range of scores is from 0 to100. A higher score is a worse score.

Time frame: 8 weeks

Population: Some subjects dropped out before completing the study.

ArmMeasureGroupValue (MEAN)Dispersion
PlacebosNeuropathic Pain ScaleWeek 140.4 score on a scaleStandard Deviation 16.7
PlacebosNeuropathic Pain ScaleWeek 535.1 score on a scaleStandard Deviation 16.4
PlacebosNeuropathic Pain ScaleWeek 337.0 score on a scaleStandard Deviation 17.2
PlacebosNeuropathic Pain ScaleBaseline45.9 score on a scaleStandard Deviation 15.2
PlacebosNeuropathic Pain ScaleWeek 834.6 score on a scaleStandard Deviation 18.3
PlacebosNeuropathic Pain ScaleWeek 736.0 score on a scaleStandard Deviation 17.8
DronabinolNeuropathic Pain ScaleWeek 334.6 score on a scaleStandard Deviation 13.6
DronabinolNeuropathic Pain ScaleBaseline45.1 score on a scaleStandard Deviation 13.5
DronabinolNeuropathic Pain ScaleWeek 138.9 score on a scaleStandard Deviation 12
DronabinolNeuropathic Pain ScaleWeek 530.8 score on a scaleStandard Deviation 14.8
DronabinolNeuropathic Pain ScaleWeek 729.6 score on a scaleStandard Deviation 14.8
DronabinolNeuropathic Pain ScaleWeek 828.2 score on a scaleStandard Deviation 16.3
Vaporized Cannabis 3.7% THC/5.6% CBDNeuropathic Pain ScaleBaseline48.3 score on a scaleStandard Deviation 15.7
Vaporized Cannabis 3.7% THC/5.6% CBDNeuropathic Pain ScaleWeek 833.2 score on a scaleStandard Deviation 20.4
Vaporized Cannabis 3.7% THC/5.6% CBDNeuropathic Pain ScaleWeek 733.4 score on a scaleStandard Deviation 19.7
Vaporized Cannabis 3.7% THC/5.6% CBDNeuropathic Pain ScaleWeek 142.3 score on a scaleStandard Deviation 15.9
Vaporized Cannabis 3.7% THC/5.6% CBDNeuropathic Pain ScaleWeek 339.2 score on a scaleStandard Deviation 19.1
Vaporized Cannabis 3.7% THC/5.6% CBDNeuropathic Pain ScaleWeek 537.5 score on a scaleStandard Deviation 17.6
p-value: 0.44unstructured covariance model
p-value: 0.53Unstructured covariance model
p-value: 0.18Unstructured covariance model
Secondary

Profile of Mood States

This questionnaire contains 65 words/statements that describe feelings people have. The questionnaire requires the patient to indicate for each word or statement how he or she has been feeling in the past week. There are 6 subscales: tension-anxiety (9 items, score range: 0-36), depression (15 items, range 0-60), anger-hostility (12 items, range 0-48), vigor-activity (8 items, range 0-32), fatigue (7 items, range 0-28), confusion-bewilderment (7 items, range 0-28). The total mood disturbance (TMD) is calculated by adding the scores for tension-anxiety, depression, anger-hostility, fatigue and confusion-bewilderment and then subtracting the score for vigor-activity. The TMD is reported and has a score range of -32 to 200. A higher score indicates worse symptoms.

Time frame: 8 weeks

Population: There were some missing data.

ArmMeasureGroupValue (MEAN)Dispersion
PlacebosProfile of Mood StatesBaseline57.3 score on a scaleStandard Deviation 32
PlacebosProfile of Mood StatesWeek 151.5 score on a scaleStandard Deviation 36.9
PlacebosProfile of Mood StatesWeek 348.6 score on a scaleStandard Deviation 30.6
PlacebosProfile of Mood StatesWeek 546.3 score on a scaleStandard Deviation 27.2
PlacebosProfile of Mood StatesWeek 745.5 score on a scaleStandard Deviation 27.3
PlacebosProfile of Mood StatesWeek 842.5 score on a scaleStandard Deviation 30.9
DronabinolProfile of Mood StatesWeek 841.0 score on a scaleStandard Deviation 28.5
DronabinolProfile of Mood StatesBaseline53.8 score on a scaleStandard Deviation 31.5
DronabinolProfile of Mood StatesWeek 540.0 score on a scaleStandard Deviation 22.7
DronabinolProfile of Mood StatesWeek 737.7 score on a scaleStandard Deviation 23.7
DronabinolProfile of Mood StatesWeek 146.2 score on a scaleStandard Deviation 23.6
DronabinolProfile of Mood StatesWeek 342.9 score on a scaleStandard Deviation 27.4
Vaporized Cannabis 3.7% THC/5.6% CBDProfile of Mood StatesWeek 141.5 score on a scaleStandard Deviation 22.2
Vaporized Cannabis 3.7% THC/5.6% CBDProfile of Mood StatesWeek 338.8 score on a scaleStandard Deviation 23.3
Vaporized Cannabis 3.7% THC/5.6% CBDProfile of Mood StatesWeek 839.7 score on a scaleStandard Deviation 26.6
Vaporized Cannabis 3.7% THC/5.6% CBDProfile of Mood StatesWeek 538.8 score on a scaleStandard Deviation 22
Vaporized Cannabis 3.7% THC/5.6% CBDProfile of Mood StatesBaseline53.2 score on a scaleStandard Deviation 30.6
Vaporized Cannabis 3.7% THC/5.6% CBDProfile of Mood StatesWeek 744.2 score on a scaleStandard Deviation 29.2
p-value: 0.1Unstructured covariance model
p-value: 0.67unstructured covariance model
p-value: 0.25unstructured covariance model
Secondary

Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)

A Task Force was convened by the NIH Pain Consortium, with the goal of developing research standards for chronic low back pain. The results included recommendations for a repeated measures dataset in order to establish greater consistency in reporting in order to facilitate comparisons among studies. The repeated measure minimal dataset is based upon scores based upon the Patient-Reported Outcomes Measurement Information System ® (PROMIS). These items yield a classification of impacts on the lives of patients that range from 1 (least impact) to 42 (greatest impact).

Time frame: 8 weeks

Population: There were some missing data

ArmMeasureGroupValue (MEAN)Dispersion
PlacebosRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Baseline21.6 score on a scaleStandard Deviation 7.29
PlacebosRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Week 118.5 score on a scaleStandard Deviation 8.97
PlacebosRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Week 317.2 score on a scaleStandard Deviation 7.4
PlacebosRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Week 516.3 score on a scaleStandard Deviation 7.7
PlacebosRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Week 716.2 score on a scaleStandard Deviation 7.42
PlacebosRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Week 815.9 score on a scaleStandard Deviation 9.06
DronabinolRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Week 815.8 score on a scaleStandard Deviation 8.53
DronabinolRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Baseline22.5 score on a scaleStandard Deviation 6.46
DronabinolRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Week 516.9 score on a scaleStandard Deviation 6.93
DronabinolRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Week 715.1 score on a scaleStandard Deviation 7.17
DronabinolRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Week 119.9 score on a scaleStandard Deviation 6.48
DronabinolRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Week 318.1 score on a scaleStandard Deviation 7.44
Vaporized Cannabis 3.7% THC/5.6% CBDRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Week 120.3 score on a scaleStandard Deviation 8.08
Vaporized Cannabis 3.7% THC/5.6% CBDRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Week 319.2 score on a scaleStandard Deviation 9.3
Vaporized Cannabis 3.7% THC/5.6% CBDRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Week 815.8 score on a scaleStandard Deviation 10.3
Vaporized Cannabis 3.7% THC/5.6% CBDRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Week 516.6 score on a scaleStandard Deviation 9.18
Vaporized Cannabis 3.7% THC/5.6% CBDRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Baseline23.1 score on a scaleStandard Deviation 7.03
Vaporized Cannabis 3.7% THC/5.6% CBDRepeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)Week 716.1 score on a scaleStandard Deviation 9.88
p-value: 0.27unstructured covariance model
p-value: 0.96unstructured covariance model
p-value: 0.3unstructured covariance model
Secondary

Wechsler Adult Intelligence Scale-III Digit Symbol Test

The Digit Symbol test measures concentration, psychomotor speed, and graphomotor abilities. This pen and paper test involves having subjects substitute a series of symbols with numbers as quickly and accurately as possible during a 120 second period. The results are expressed as the number of correct substitutions with a score range of 0-133. A higher number indicates better performance.

Time frame: 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
PlacebosWechsler Adult Intelligence Scale-III Digit Symbol TestBaseline80.3 number of correct symbolsStandard Deviation 14.9
PlacebosWechsler Adult Intelligence Scale-III Digit Symbol TestWeek 184.8 number of correct symbolsStandard Deviation 17.2
PlacebosWechsler Adult Intelligence Scale-III Digit Symbol TestWeek 388.9 number of correct symbolsStandard Deviation 17.5
PlacebosWechsler Adult Intelligence Scale-III Digit Symbol TestWeek 590.0 number of correct symbolsStandard Deviation 19.7
PlacebosWechsler Adult Intelligence Scale-III Digit Symbol TestWeek 788.4 number of correct symbolsStandard Deviation 20.9
PlacebosWechsler Adult Intelligence Scale-III Digit Symbol TestWeek 884.8 number of correct symbolsStandard Deviation 22.6
DronabinolWechsler Adult Intelligence Scale-III Digit Symbol TestWeek 879.3 number of correct symbolsStandard Deviation 21.9
DronabinolWechsler Adult Intelligence Scale-III Digit Symbol TestBaseline69.6 number of correct symbolsStandard Deviation 17.2
DronabinolWechsler Adult Intelligence Scale-III Digit Symbol TestWeek 579.2 number of correct symbolsStandard Deviation 20.9
DronabinolWechsler Adult Intelligence Scale-III Digit Symbol TestWeek 779.8 number of correct symbolsStandard Deviation 19.8
DronabinolWechsler Adult Intelligence Scale-III Digit Symbol TestWeek 173.5 number of correct symbolsStandard Deviation 19.3
DronabinolWechsler Adult Intelligence Scale-III Digit Symbol TestWeek 375.6 number of correct symbolsStandard Deviation 18.2
Vaporized Cannabis 3.7% THC/5.6% CBDWechsler Adult Intelligence Scale-III Digit Symbol TestWeek 178.3 number of correct symbolsStandard Deviation 16.7
Vaporized Cannabis 3.7% THC/5.6% CBDWechsler Adult Intelligence Scale-III Digit Symbol TestWeek 377.6 number of correct symbolsStandard Deviation 19.7
Vaporized Cannabis 3.7% THC/5.6% CBDWechsler Adult Intelligence Scale-III Digit Symbol TestWeek 887.3 number of correct symbolsStandard Deviation 18.6
Vaporized Cannabis 3.7% THC/5.6% CBDWechsler Adult Intelligence Scale-III Digit Symbol TestWeek 583.1 number of correct symbolsStandard Deviation 18.8
Vaporized Cannabis 3.7% THC/5.6% CBDWechsler Adult Intelligence Scale-III Digit Symbol TestBaseline72.2 number of correct symbolsStandard Deviation 15.6
Vaporized Cannabis 3.7% THC/5.6% CBDWechsler Adult Intelligence Scale-III Digit Symbol TestWeek 781.0 number of correct symbolsStandard Deviation 21.3
p-value: 0.89Unstructured covariance model
p-value: 0.13unstructured covariance model
p-value: 0.14unstructured covariance model

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026